Vitamin B6 Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Vitamin B6 dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Vitamin B6.
Dosing Protocols
The Beginner Protocol covers general population B6 adequacy and the most common indication: nausea of pregnancy. For general adults, 1.3–1.7 mg/day RDA is easily met by a varied diet including poultry, fish, potatoes, bananas, and fortified grains; supplementation is rarely needed outside a standard B-complex or multivitamin. For women in first-trimester pregnancy with nausea (NVP), pyridoxine 10–25 mg every 8 hours is first-line therapy, often combined with doxylamine 10 mg (as Diclegis/Bonjesta) with the pyridoxine-doxylamine combination being ACOG first-line for NVP with excellent safety and efficacy data. Dose escalation to 4 tablets daily (40 mg pyridoxine + 40 mg doxylamine total) is standard if single-dose therapy is inadequate. Pyridoxine alone at 25 mg three times daily is effective per Sahakian 1991 and can be used if doxylamine is unavailable or causes excessive sedation. For isoniazid prophylaxis during TB treatment, 25–50 mg pyridoxine daily alongside INH is standard of care to prevent peripheral neuropathy. Take B6 with or without food at any time of day; absorption is good either way. The Beginner Protocol specifically does NOT include chronic supplementation above 100 mg/day — this is the tolerable upper limit and doses above it risk sensory neuropathy over months to years. If you are considering long-term higher doses for premenstrual syndrome, carpal tunnel syndrome, or other indications with modest evidence, keep total daily dose at or below 100 mg and monitor for any sensory symptoms. For premenstrual syndrome specifically, 50–100 mg/day during the luteal phase is reasonable based on Wyatt 1999 meta-analysis showing modest symptom improvement (PMID 10334745). For most healthy adults, a B-complex providing 10–25 mg B6 (as pyridoxine HCl or P5P) is more than adequate.
The Intermediate Protocol addresses confirmed B6 deficiency, homocysteine elevation, sideroblastic anemia responsive to pyridoxine, persistent NVP, carpal tunnel trial, and PMS at the high end of evidence-supported doses. For confirmed B6 deficiency (low plasma PLP typically <20 nmol/L, or elevated urinary xanthurenic acid after tryptophan load as functional marker), start 25–50 mg/day pyridoxine HCl or P5P for 1–3 months with recheck of plasma PLP or clinical response. Identify the underlying cause: chronic alcohol use, isoniazid use, theophylline use, celiac/IBD malabsorption, hemodialysis, penicillamine use, or dietary inadequacy. For homocysteine elevation with no clear folate or B12 deficiency: 25–50 mg B6 + 400–800 mcg folate + 500–1,000 mcg B12 daily; recheck homocysteine at 2–3 months. For sideroblastic anemia (acquired or hereditary ALAS2-responsive subtype), 100–200 mg/day pyridoxine for 1–3 months trial; responders continue chronic supplementation with hematology monitoring. For persistent NVP not controlled by standard Diclegis dosing, escalate pyridoxine to 25 mg three times daily alongside doxylamine 25 mg at bedtime plus 12.5 mg in morning and mid-afternoon as needed, under OB supervision; add ondansetron or metoclopramide if still inadequate. For premenstrual syndrome at maximum evidence-supported dose, 100 mg/day during luteal phase only (typically days 14–28 of cycle), with attention to any sensory symptoms; do not continue indefinitely without periodic reassessment. For carpal tunnel syndrome, B6 is not first-line therapy — wrist splinting, steroid injection, and surgical decompression have much stronger evidence. B6 200 mg/day for 2–3 months can be tried as an adjunct in patients with equivocal B6 status and mild-to-moderate CTS, with clear stopping rules at any sensory symptoms or at 3 months without clear benefit. Do not continue chronic B6 above 100 mg/day in an uncomplicated CTS patient without specialist guidance. For chronic kidney disease on hemodialysis, B6 losses in dialysate warrant supplementation typically 5–10 mg/day. For gestational hypertension or preeclampsia, B6 has been explored without strong evidence of benefit beyond standard prenatal doses; no high-dose indication currently.
The Advanced Protocol covers specialist-directed high-dose B6 therapy for pyridoxine-responsive inborn errors of metabolism, pyridoxine-dependent epilepsy, and other rare specialist indications. Pyridoxine-dependent epilepsy (PDE, ALDH7A1 mutations) is a treatable cause of intractable neonatal and infant seizures and warrants an IV pyridoxine trial in any unexplained refractory seizure in infancy: 100 mg IV pyridoxine while monitoring EEG can terminate seizures within minutes in affected infants, with dramatic clinical improvement. Confirmed PDE patients are maintained on oral pyridoxine typically 15–30 mg/kg/day (up to 500 mg/day in adults) lifelong, with some recent trials supporting lysine restriction and arginine supplementation as adjuncts to reduce pipecolic acid/α-aminoadipic semialdehyde accumulation — specialist pediatric neurology and metabolic medicine management. Newer forms of B6-responsive epilepsy include PNPO deficiency (responds to PLP or pyridoxal, not pyridoxine) and hyperprolinemia type 2. Homocystinuria from cystathionine β-synthase (CBS) deficiency: about 50% of affected patients respond to pyridoxine 100–500 mg/day with substantial homocysteine lowering and avoidance of thromboembolic complications. Responders are distinguished by lower residual CBS activity and benefit from lifelong pyridoxine. Non-responders require protein restriction, betaine, folate, cysteine supplementation, and sometimes vitamin K. Genetic and enzymatic testing guide treatment. Secondary hyperoxaluria and primary hyperoxaluria: some subtypes (especially primary hyperoxaluria type I, AGXT deficiency) respond to pyridoxine by shifting glyoxylate metabolism; doses of 5–20 mg/kg/day are used with urology/nephrology oversight. Sideroblastic anemias: hereditary X-linked sideroblastic anemia from ALAS2 mutations and some acquired sideroblastic anemias respond to pyridoxine 100–500 mg/day; response is monitored by hemoglobin and reticulocyte count. Isoniazid overdose: acute isoniazid poisoning produces seizures by depleting functional B6 and impairing GABA synthesis, treated with IV pyridoxine gram-for-gram matching the ingested isoniazid dose (or empirically 5 g for unknown ingestions) — a specific ICU/toxicology protocol. Gyromitrin mushroom poisoning (Gyromitra false morels): acute toxicity with hepatic damage and seizures, treated with IV pyridoxine at high doses given the monomethylhydrazine mechanism mimicking isoniazid. Ethylene glycol co-ingestion in some toxicology protocols. Vitamin B6-responsive gyrate atrophy of the retina (OAT deficiency): responds to pyridoxine and arginine restriction in some subtypes. The Advanced tier is entirely specialist territory — pediatric neurology, metabolic medicine, hematology, nephrology, toxicology — with high-dose pyridoxine (hundreds of mg to grams in acute settings) used for defined genetic or toxicological indications with objective response monitoring.
Commonly Stacked With
B6 stacks most naturally with Folate and Vitamin B12 in the classic homocysteine-lowering trio. The three vitamins address homocysteine metabolism from complementary angles: folate + B12 drive remethylation of homocysteine back to methionine via methionine synthase; B6 drives transsulfuration of homocysteine to cystathionine and cysteine via CBS. A typical homocysteine-lowering stack is 400–800 mcg folate + 500–1,000 mcg B12 + 25–50 mg B6 daily, which reliably lowers homocysteine by 20–30%. The evidence for cardiovascular benefit from this homocysteine lowering has been disappointing in folate-replete populations (NORVIT, HOPE-2, VISP, SEARCH, WAFACS) but remains relevant for documented hyperhomocysteinemia, homocystinuria, and possibly stroke prevention in folate-deficient populations (Chinese CSPPT trial). B6 and Magnesium: magnesium is a cofactor for pyridoxal kinase (the enzyme converting pyridoxal to active PLP), and magnesium deficiency can functionally impair B6 activation. Combined B6 + magnesium has been tested in premenstrual syndrome and autism with modest behavioral signals in some trials; the theoretical synergy is reasonable and the stacking is low-risk at standard doses. B6 and Zinc: zinc is also a cofactor in pyridoxine kinase activation of B6. Combined B6-zinc-magnesium (so-called "trace mineral methylation support" stacks) has logical biochemical grounding for patients with methylation concerns, though outcome trials of this specific combination are limited. B6 and Glycine: glycine is a substrate for ALAS (the B6-dependent heme synthesis enzyme) and for serine hydroxymethyltransferase (the B6-dependent one-carbon entry point). B6 supports glycine's metabolic contributions; this is a complementary relationship rather than competitive. B6 and Iron: B6 is required for heme synthesis via ALAS, and some sideroblastic anemias respond to pyridoxine. In the anemia differential, if iron studies are normal but a microcytic picture persists, check B6 status alongside B12 and folate. B6 and Vitamin C: no direct interaction at standard doses. B6 and Alpha-Lipoic Acid: no direct interaction. B6 and CoQ10: no direct interaction; both support mitochondrial and cellular energy metabolism in complementary but distinct ways. B6 and Omega-3 fatty acids: no direct interaction. B6 and levodopa (Parkinson disease): historically B6 enhanced peripheral AADC decarboxylation of levodopa and reduced CNS delivery, creating "avoid B6 in Parkinson's" guidance. Modern carbidopa-levodopa and benserazide-levodopa combinations peripherally inhibit AADC and largely eliminate this interaction — B6 supplementation within RDA range is safe in Parkinson patients on modern combination levodopa therapy. B6 and phenytoin: B6 at pharmacologic doses can lower phenytoin levels and compromise seizure control; coordinate carefully if both are needed. B6 and isoniazid: protective interaction — isoniazid depletes B6 by forming a pyridoxine hydrazone and causes peripheral neuropathy in deficient patients. Pyridoxine 25–50 mg/day during TB treatment prevents isoniazid neuropathy and is standard prophylaxis. B6 and doxylamine: the classical first-line combination for nausea of pregnancy, with excellent safety and efficacy data. B6 and theophylline: theophylline inhibits pyridoxal kinase and depletes functional B6; supplementation is reasonable for chronic theophylline users. B6 and alcohol: chronic heavy alcohol use impairs B6 metabolism and accelerates PLP degradation; supplementation is standard in alcohol-related nutritional rehabilitation. B6 and oral contraceptives: modest B6 lowering from OCs has been documented but is not typically clinically significant; no routine supplementation needed. B6 and penicillamine: penicillamine reacts with pyridoxal and depletes B6; supplementation indicated with chronic penicillamine use. Timing: B6 can be taken any time of day with or without food; absorption is good either way. Morning dosing with a B-complex or multivitamin is standard. Split dosing may be useful for high-dose indications to minimize peak-dose GI discomfort. The cleanest stacking synthesis: B6 + folate + B12 is the homocysteine-lowering triad; B6 + magnesium + zinc is the activation/cofactor triad; isoniazid prophylaxis uses B6 alone at 25–50 mg; pregnancy NVP uses B6 + doxylamine; high-dose B6 for homocystinuria or PDE is specialist-directed.
Side Effects & Safety
Contraindications
B6 is generally very safe at RDA-range dosing but warrants caution in several contexts. Chronic high-dose pyridoxine above 100 mg/day (the tolerable upper limit) is a relative contraindication for general use — the sensory peripheral neuropathy / ganglionopathy syndrome described by Schaumburg 1983 can develop at chronic doses above 200 mg/day with insidious onset and variable reversibility, and doses above the UL should have a specific clinical indication. Patients on chronic B6 for PMS, CTS, or other indications should stop or reduce dose at any sensory symptoms and should avoid long-term multi-year supplementation above 100 mg/day without specialist oversight. Pregnancy: RDA-range B6 and pyridoxine-doxylamine at NVP treatment doses (up to 40 mg pyridoxine/day total) are safe with decades of safety data. Very high-dose B6 in pregnancy outside specific metabolic indications is not studied and should be avoided. Breastfeeding: RDA-range B6 is safe; very high-dose maternal pyridoxine (above 200 mg/day) has been reported to suppress lactation in some case reports, and high-dose B6 should be avoided in breastfeeding mothers unless specifically indicated. Pediatric: RDA-range B6 is safe; high-dose pyridoxine for PDE is pediatric neurology territory with careful dose titration; inadvertent high-dose B6 from adult multivitamin exposure is a concern for infants and young children and warrants storage safety. Parkinson disease on pure levodopa (without carbidopa): B6 accelerates peripheral decarboxylation and reduces CNS levodopa delivery — this is historical and mostly irrelevant now given universal use of carbidopa-levodopa or benserazide-levodopa combinations, but pure levodopa patients (rarely encountered) should avoid pharmacologic B6. Modern combination levodopa patients can safely take RDA-range B6. Phenytoin therapy: pharmacologic B6 lowers phenytoin levels and can compromise seizure control; coordinate with neurology if both are needed. Phenobarbital levels also can drop with pharmacologic B6. Altretamine (hexamethylmelamine) chemotherapy: B6 reduces efficacy and is contraindicated during treatment. True allergic reactions to pyridoxine are rare. Renal disease on hemodialysis: B6 losses in dialysate warrant supplementation typically 5–10 mg/day, and patients should be on appropriate replacement dose. Celiac disease, inflammatory bowel disease, bariatric surgery: B6 absorption may be impaired and supplementation may be needed. Alcoholism: chronic heavy alcohol use impairs B6 metabolism; B6 supplementation is standard in alcohol-related nutritional rehabilitation alongside thiamine, folate, and B12. Isoniazid therapy: pyridoxine 25–50 mg/day is protective, not contraindicated — this is standard prophylaxis to prevent INH neuropathy. Theophylline therapy: B6 supplementation is reasonable given theophylline's inhibition of pyridoxal kinase. Penicillamine therapy (Wilson disease, RA): penicillamine depletes B6 via Schiff base formation with pyridoxal; supplementation is indicated. Levodopa without carbidopa (rare): contraindicated at pharmacologic doses. Drug interactions warranting attention: isoniazid (protective), theophylline (protective), penicillamine (protective), phenytoin (dose coordination), phenobarbital (dose coordination), altretamine (avoid during chemo), levodopa without carbidopa (avoid pharmacologic B6), oral contraceptives (modest B6 depletion). Overall B6 is very safe at RDA-range, moderate safety profile at NVP treatment doses, and warrants monitoring at chronic doses above 100 mg/day with clear stopping rules at any sensory symptoms. This is general educational content, not medical advice.
Additional Notes
Dosing B6 requires distinguishing pyridoxine forms. Pyridoxine HCl is the most common supplemental form, inexpensive, and the basis of the outcome evidence for NVP, INH prophylaxis, and most clinical uses. P5P (pyridoxal 5-phosphate, active coenzyme form) is more expensive and marketed as "pre-activated" B6, bypassing the kinase step that converts pyridoxine to PLP; for most healthy people P5P confers no meaningful advantage over pyridoxine HCl and may be indicated only in specific PNPO deficiency contexts where pyridoxine does not respond. Pyridoxal 5-phosphate must be dephosphorylated at the gut lumen before absorption as pyridoxal, so the "pre-activated" marketing is somewhat misleading — what matters is adequate absorption and tissue delivery, which both forms achieve at standard doses. Dosing for common indications: general adult RDA 1.3–1.7 mg/day (easily met by diet or any B-complex); pregnancy RDA 1.9 mg, lactation 2.0 mg. NVP in pregnancy: 10–25 mg every 8 hours pyridoxine, usually combined with doxylamine 10 mg (Diclegis) up to 4 tablets daily. INH prophylaxis: 25–50 mg daily during TB treatment. Premenstrual syndrome: 50–100 mg daily or luteal-phase only. Homocysteine lowering: 25–50 mg daily with folate + B12. Homocystinuria (CBS deficiency): 100–500 mg/day, titrated for homocysteine response, under metabolic medicine oversight. Pyridoxine-dependent epilepsy: 15–30 mg/kg/day (up to 500 mg adult) lifelong. Sideroblastic anemia: 100–500 mg/day trial, continued if responsive. Isoniazid overdose: 5 g IV empirically or gram-for-gram if ingestion dose known. Gyromitra poisoning: 25 mg/kg IV up to 25 g total. Primary hyperoxaluria type I: 5–20 mg/kg/day. Hemodialysis: 5–10 mg/day to replace dialysate losses. Tolerable upper limit is 100 mg/day synthetic pyridoxine — doses above this should have a specific clinical indication and monitoring for sensory neuropathy. Typical supplements provide B6 as 1.7–100 mg per capsule. Avoid chronic supplementation above 100 mg/day for general use; if higher dose is needed, duration should be defined and sensory symptoms monitored. Take B6 with or without food; absorption is good either way. Morning dosing with a B-complex is standard. Split dosing is reasonable for high-dose indications to minimize peak-dose GI discomfort. Lab monitoring: plasma PLP (pyridoxal 5-phosphate) is the standard biomarker of B6 status, reference range typically 20–125 nmol/L but varies by lab; urinary 4-pyridoxic acid can be used; xanthurenic acid after tryptophan load is a functional marker but rarely used clinically. For NVP, PDE, homocystinuria, and sideroblastic anemia, clinical response (symptom control, homocysteine lowering, hematologic response, seizure control) is the primary monitoring endpoint rather than plasma PLP per se. For high-dose chronic supplementation, periodic neurologic symptom assessment and plasma PLP monitoring are reasonable, with dose reduction if sensory symptoms emerge.
Frequently Asked Questions
What is the recommended Vitamin B6 dosage?
Dosage for Vitamin B6 varies by protocol. Consult a qualified healthcare provider.
How often should I take Vitamin B6?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Vitamin B6 need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Vitamin B6 side effects?
B6 at RDA-range dietary doses is extremely safe, but the side effect profile at chronic pharmacologic doses is more concerning than most water-soluble vitamins. The hallmark toxicity is a distinctive sensory peripheral neuropathy or sensory ganglionopathy described by Schaumburg in 1983 in patients taking multi-gram pyridoxine doses for years, characterized by burning dysesthesias in the feet, gait unsteadiness, positive sensory symptoms, and in severe cases reduced proprioception with pseudoathetoid movements of outstretched hands — a picture suggesting dorsal root ganglion damage rather than typical distal dying-back neuropathy. Subsequent case series documented the syndrome at sustained doses as low as 200–500 mg/day over months to years, and modern analyses continue to show neuropathy cases at chronic doses above the 100 mg/day UL. The practical implication is that "therapeutic" high-dose B6 (above 100 mg/day) should have a specific clinical indication — NVP with doxylamine, homocystinuria, PDE, PMS at max 100 mg, isoniazid prophylaxis at 25–50 mg — and should not be continued indefinitely without attention to sensory symptoms. Patients on chronic B6 above 200 mg/day should be periodically assessed for early neuropathic symptoms (tingling, burning, unsteadiness) and dose reduced or stopped at first signs. The neuropathy may not fully reverse after stopping high-dose B6, though most patients have partial recovery over months. Beyond neuropathy, acute high-dose B6 can cause photosensitivity skin reactions, GI upset, and rarely anaphylactoid reactions. Pyridoxine's interaction with levodopa is historically famous: pharmacologic B6 enhances peripheral decarboxylation of levodopa (via AADC) and reduces the fraction reaching the CNS, worsening Parkinson disease symptoms in patients on levodopa without carbidopa. Modern Parkinson regimens with carbidopa or benserazide peripherally inhibit AADC and largely eliminate this interaction, so the "avoid B6 in Parkinson disease" rule is outdated for patients on modern combination levodopa; it remains relevant if someone is somehow on pure levodopa. Pyridoxine reduces phenytoin levels and can compromise seizure control — coordinate with neurology if both are needed. Pyridoxine interferes with phenobarbital. Pyridoxine supplementation with isoniazid is protective, not a concern. Pyridoxine with penicillamine (chelator used in Wilson disease, rheumatoid arthritis) is actually complementary, since penicillamine can cause B6 deficiency. Pyridoxine with theophylline is protective — theophylline inhibits pyridoxal kinase and depletes functional B6. Pyridoxine reduces the efficacy of altretamine (chemotherapy), so should be avoided during that treatment. Pyridoxine can interact with alcohol in increasing hepatic clearance of benzodiazepines. GI side effects (nausea, abdominal discomfort, constipation) can occur with high-dose pyridoxine especially on empty stomach. Photosensitive skin reactions have been reported. Rarely, injection-site reactions with IV pyridoxine. Pregnancy: RDA-range B6 is safe; pyridoxine-doxylamine (Diclegis) is ACOG first-line for NVP with excellent safety data over decades of use. Breastfeeding: B6 transfers to breast milk; RDA-range maternal intake supports infant needs, and very high-dose maternal pyridoxine (above 200 mg/day) has been associated with suppression of lactation in some reports — generally avoid high-dose B6 in breastfeeding mothers unless specifically indicated. Pediatric: RDA-range and pediatrician-directed; high-dose pyridoxine for PDE or other indications is pediatric neurology or metabolic medicine territory. The cleanest safety summary: RDA-range B6 is extremely safe; NVP pyridoxine-doxylamine doses are well-tolerated and safe in pregnancy; chronic supplementation above 100 mg/day requires a specific clinical indication and monitoring for sensory neuropathy; doses above 500 mg/day should only be used in specialist-directed protocols for PDE, homocystinuria, or sideroblastic anemia.
Where can I buy Vitamin B6?
Visit our vendor directory to find trusted sources for Vitamin B6.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
